SPRY
ARS Pharmaceuticals, Inc.
Biotechnology
Market Cap$894M
5Y Perf.-81.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SPRY vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-24.7%
SPRY vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SPRY | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $894M | $1712.35T |
| Revenue (TTM) | $84M | $0.00 |
| Net Income (TTM) | $-171M | $-168M |
| Gross Margin | 54.4% | — |
| Operating Margin | -212.9% | — |
| Total Debt | $0.00 | $22M |
| Cash & Equiv. | $41M | $194M |
SPRY vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SPRY
DBVT
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| ARS Pharmaceuticals… (SPRY) | 100 | 18.9 | -81.1% |
| DBV Technologies S.… (DBVT) | 100 | 75.3 | -24.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SPRY vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: DBVT leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. ARS Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
SPRY
ARS Pharmaceuticals, Inc.
The Growth Play
SPRY is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth -5.5%, EPS growth -23.3%, 3Y rev CAGR 300.1%
- -64.0% 10Y total return vs DBVT's -87.0%
- -5.5% revenue growth vs DBVT's -100.0%
Best for: growth exposure and long-term compounding
DBVT
DBV Technologies S.A.
The Income Pick
DBVT carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 1.26
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
- Beta 1.26, current ratio 3.67x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SPRY | -5.5% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs SPRY's -203.3% |
| Stability / Safety | DBVT | Beta 1.26 vs SPRY's 1.47 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +110.4% vs SPRY's -33.3% |
| Efficiency (ROA) | SPRY | -51.1% ROA vs DBVT's -89.0% |
SPRY vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
SPRY vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSPRYLAGGINGDBVT
DBVTDBV Technologies S.A.
2leads
SPRYARS Pharmaceuticals, …
2leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SPRY4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
SPRY4/6
Risk & VolatilityBeta, volatility, and downside exposure
DBVT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SPRY and DBVT operate at a comparable scale, with $84M and $0 in trailing revenue.
| Metric | SPRYARS Pharmaceutica… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $84M | $0 |
| EBITDAEarnings before interest/tax | -$178M | -$112M |
| Net IncomeAfter-tax profit | -$171M | -$168M |
| Free Cash FlowCash after capex | -$171M | -$151M |
| Gross MarginGross profit ÷ Revenue | +54.4% | — |
| Operating MarginEBIT ÷ Revenue | -2.1% | — |
| Net MarginNet income ÷ Revenue | -2.0% | — |
| FCF MarginFCF ÷ Revenue | -2.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -67.6% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -180.4% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — SPRY and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | SPRYARS Pharmaceutica… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $894M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $852M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -5.17x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 10.60x | — |
| Price / BookPrice ÷ Book value/share | 7.76x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — SPRY and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
SPRY leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
SPRY delivers a -100.3% return on equity — every $100 of shareholder capital generates $-100 in annual profit, vs $-130 for DBVT. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs SPRY's 3/9, reflecting mixed financial health.
| Metric | SPRYARS Pharmaceutica… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -100.3% | -130.2% |
| ROA (TTM)Return on assets | -51.1% | -89.0% |
| ROICReturn on invested capital | -96.5% | — |
| ROCEReturn on capital employed | -58.2% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | — | 0.13x |
| Net DebtTotal debt minus cash | -$41M | -$172M |
| Cash & Equiv.Liquid assets | $41M | $194M |
| Total DebtShort + long-term debt | $0 | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x |
SPRY leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
SPRY leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SPRY five years ago would be worth $3,196 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs SPRY's -33.3%. The 3-year compound annual growth rate (CAGR) favors SPRY at 14.4% vs DBVT's 6.2% — a key indicator of consistent wealth creation.
| Metric | SPRYARS Pharmaceutica… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | -21.7% | +4.9% |
| 1-Year ReturnPast 12 months | -33.3% | +110.4% |
| 3-Year ReturnCumulative with dividends | +49.8% | +19.7% |
| 5-Year ReturnCumulative with dividends | -68.0% | -69.1% |
| 10-Year ReturnCumulative with dividends | -64.0% | -87.0% |
| CAGR (3Y)Annualised 3-year return | +14.4% | +6.2% |
SPRY leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
DBVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than SPRY's 1.47 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs SPRY's 47.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SPRYARS Pharmaceutica… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.47x | 1.26x |
| 52-Week HighHighest price in past year | $18.90 | $26.18 |
| 52-Week LowLowest price in past year | $6.66 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +47.6% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 66.1 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 252K |
DBVT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SPRY as "Hold" and DBVT as "Buy". Consensus price targets imply 183.3% upside for SPRY (target: $26) vs 131.8% for DBVT (target: $46).
| Metric | SPRYARS Pharmaceutica… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $25.50 | $46.33 |
| # AnalystsCovering analysts | 10 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DBVT leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). SPRY leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Best OverallARS Pharmaceuticals, Inc. (SPRY)Leads 2 of 6 categories
Loading custom metrics...
SPRY vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SPRY or DBVT a better buy right now?
Analysts rate DBV Technologies S.
A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SPRY or DBVT?
Over the past 5 years, ARS Pharmaceuticals, Inc.
(SPRY) delivered a total return of -68. 0%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: SPRY returned -65. 0% versus DBVT's -87. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SPRY or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus ARS Pharmaceuticals, Inc. 's 1. 47β — meaning SPRY is approximately 17% more volatile than DBVT relative to the S&P 500.
04Which is growing faster — SPRY or DBVT?
On earnings-per-share growth, the picture is similar: DBV Technologies S.
A. grew EPS -347. 5% year-over-year, compared to -23. 3% for ARS Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SPRY or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -203. 3% for ARS Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -212. 9% for SPRY. At the gross margin level — before operating expenses — SPRY leads at 54. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SPRY or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SPRY or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DBV Technologies S.
A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Both have compounded well over 10 years (DBVT: -87. 1%, SPRY: -65. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SPRY and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.